103628-48-4
103628-48-4
Chemical Structure
Sumatriptan succinate
Synonym(s): GR 43175 succinate
- CAS No.: 103628-48-4
- Formula:C18H27N3O6S
- Molecular Weight:413.49
IUPAC Name: 1-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide succinate
InChIKey: PORMUFZNYQJOEI-UHFFFAOYSA-N
SMILES: O=C(O)CCC(O)=O.O=S(CC1=CC2=C(NC=C2CCN(C)C)C=C1)(NC)=O
Biological Activity: Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan succinate can be used for migraine headache research[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sumatriptan succinate | 99.89% | Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan succinate can be used for migraine headache research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sumatriptan succinate (Standard) | ≥98% | Sumatriptan (succinate) (Standard) is the analytical standard of Sumatriptan (succinate). This product is intended for research and analytical applications. Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sumatriptan-d6 succinate | 99.63% | Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. S J Peroutka, et al. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol. 1989 Apr 12;163(1):133-6. [Content Brief]
- [2]. K L Dechant, et al. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1992 May;43(5):776-98. [Content Brief]
- [3]. Razzaque Z, et al. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Br J Clin Pharmacol. 1999 Jan;47(1):75-82. [Content Brief]
- [4]. Bates EA, et al. Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia. 2010 Feb;30(2):170-8. [Content Brief]
